Zalunfiban Shows Promise at AHA Scientific Sessions
Slice of Healthcare Team
11/15/2025
Key highlights
- Zalunfiban shows efficacy in STEMI treatment
- Phase 3 trial conducted on 2,467 patients
- Quick antiplatelet effects aid emergency response
- Developed with support from Harrington Discovery Institute
- A promising advancement in cardiovascular medicine
Source: PR Newswire
Notable Quotes
“ My therapeutics development advisory team at Harrington Discovery Institute played a crucial role in where we are today. ”
Barry Coller, MD, Vice President for Medical Affairs at The Rockefeller University
“ Dr. Coller's work is an excellent example of our mission being accomplished. ”
Jonathan S. Stamler, MD, President and Co-Founder at Harrington Discovery Institute
Why this matters
The announcement of zalunfiban's positive clinical trial results represents a significant advancement in the treatment of heart attacks (STEMI), potentially transforming emergency medical protocols and improving patient outcomes in critical situations. This development is particularly significant for the healthcare sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
